Search clinical trials for: AZD6370

Total 68 results

AstraZeneca

Completed

A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients

Type 2 Diabetes

Sweden
AstraZeneca
Karolinska Institutet, Quintiles IMS

Completed

AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers

Healthy Volunteer Male Subjects

Sweden
AstraZeneca

Active, not recruiting

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Advanced Solid Tumours

United States, France, Spain
AstraZeneca

Completed

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

Asthma

United States, Germany, United Kingdom
Massachusetts General Hospital
AstraZeneca

Recruiting

AZD6738 for Patients With Progressive MDS or CMML

Leukemia | Myelodysplastic Syndrome

United States
AstraZeneca

Completed

AZD6280 Multiple Ascending Dose Study (MAD)

Healthy Volunteer

United States
Royal Marsden NHS Foundation Trust
AstraZeneca; Cancer Research UK; RM/ICR Biomedical Research Centre

Active, not recruiting

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours (Patriot)

Solid Tumour Refractory to Conventional Treatment

United Kingdom
AstraZeneca

Recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. (PRIMAVERA)

Lymphoma | Hodgkin Lymphoma | Non-Hodgkin

Korea, Republic of, United Kingdom, Italy, Germany, France, Spain, United States, Australia
AstraZeneca

Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours (PRIMROSE)

Advanced Solid Tumours That Are MTAP Deficient

United States, Spain, Korea, Republic of, Australia, Japan, China, Netherlands, France
Nader Sanai
AstraZeneca; Barrow Neurological Institute; Ivy Brain Tumor Center

Recruiting

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

Glioma | Glioblastoma | Glioblastoma Multiforme | Glioma, Malignant

United States
University of Leeds
University College London Hospitals; The Leeds Teaching Hospitals NHS Trust; University... and other collaborators

Recruiting

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE)

Non Small Cell Lung Cancer

United Kingdom
AstraZeneca

Completed

AZD8330 First Time in Man in Patients With Advanced Malignancies

Cancer

United States, Norway
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
The Netherlands Cancer Institute
Leiden University Medical Center; University Medical Center Nijmegen

Recruiting

Sarcomas and DDR-Inhibition; a Combined Modality Study (SADDRIN-1)

Soft Tissue Sarcoma Adult

Netherlands
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

Solid Tumor | Metastatic Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Solid Carcinoma | Metastatic Tumor

United States
AstraZeneca
Parexel

Completed

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

Healthy Volunteers

United States
AstraZeneca
Parexel

Completed

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

Healthy Volunteers

United States
AstraZeneca

Recruiting

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Recurrent Glioblastoma Multiforme | Brain Neoplasms, Malignant | Primary Glioblastoma Multiforme | Leptomeningeal Disease (LMD)

United States, United Kingdom
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
Seoul National University Hospital

Recruiting

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
Se-Hoon Lee
AstraZeneca

Completed

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects (SUKSES-N4)

Small Cell Lung Cancer

Korea, Republic of
University of Nottingham

Completed

Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.

Insulin Resistance | Age Problems

United Kingdom
AstraZeneca

Active, not recruiting

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Non-Small Cell Lung Cancer

France, Spain, United States, Canada, Korea, Republic of, Austria, Israel, Germany
Mette M Berger
Texas A&M University

Completed

Can Beta-Hydroxy-beta-Methylbutyrate Supplementation Counteract Muscle Catabolism in Critically Ill Patients? (HMB-ICU-CH)

Critical Illness | Muscle Weakness

Switzerland
Samsung Medical Center

Active, not recruiting

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Gastric Adenocarcinoma | Malignant Melanoma

Korea, Republic of
University of Chicago
National Cancer Institute (NCI)

Completed

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Precancerous Condition | Lip and Oral Cavity Squamous Cell Carcinoma | Oral Cavity Verrucous Carcinoma

United States
AstraZeneca

Completed

Uric Acid Study in Healthy Male Volunteers

Coronary Artery Disease | Gout
Samsung Medical Center

Completed

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

SCLC

Korea, Republic of
University of Pennsylvania
AstraZeneca; Myriad Genetics, Inc.

Recruiting

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)

High Grade Serous Carcinoma

United States
AstraZeneca

Completed

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Head and Neck Squamous Cell Carcinoma

Taiwan, United States, France
University of Michigan Rogel Cancer Center

Active, not recruiting

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Prostate Cancer

United States
Samsung Medical Center

Completed

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Refractory Cancer

Korea, Republic of
Institute of Cancer Research, United Kingdom
AstraZeneca; Cancer Research UK

Recruiting

ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI)

Gynaecological Cancers

United Kingdom
Institute of Cancer Research, United Kingdom
AstraZeneca

Recruiting

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX)

Breast Neoplasm

United Kingdom
Dana-Farber Cancer Institute
AstraZeneca; Osteosarcoma Institute

Recruiting

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Osteosarcoma | Osteosarcoma Recurrent

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Medical Center

Completed

Sodium Stibogluconate Treatment of Leishmaniasis

Leishmaniasis

United States
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 (PET)

Anxiety

Sweden
Tribhuvan University, Nepal

Completed

Does Antibiotics Use During Surgery Help to Decrease Wound Infection and Increase Success After Ear Surgery in Children

Post Operative Wound Infection | Graft Uptake | Myringoplasty
Seoul National University Hospital

Active, not recruiting

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
Joseph Paul Eder
Dana-Farber Cancer Institute; The Cleveland Clinic; Vanderbilt-Ingram Cancer...

Terminated

OLAParib COmbinations (OLAPCO)

Cancer

United States
AstraZeneca
Parexel

Withdrawn

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (DUETTE)

Ovarian Cancer

United States, Italy, Canada, Spain
AstraZeneca

Completed

Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers

Healthy

Japan
IFOM ETS - The AIRC Institute of Molecular Oncology
AstraZeneca

Recruiting

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel (ATRiBRAVE)

Triple Negative Breast Cancer Metastatic

Italy
Assistance Publique Hopitaux De Marseille

Recruiting

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR)

Non-small Cell Lung Cancer

France
University of Edinburgh
AstraZeneca

Completed

DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury (DIAMOND)

Coronary Artery Disease

United Kingdom
AstraZeneca

Completed

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

Renal Impairment

United States
AstraZeneca

Completed

An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers

Pharmacokinetics

China
AstraZeneca

Completed

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO)

Acute Coronary Syndrome

Sweden, United States, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, South Africa, Turkey, United Kingdom, Germany, Philippines, China, Hungary, Romania, Denmark, Netherlands, Norway, C... and more
CCTU- Cancer Theme
AstraZeneca

Recruiting

AZD6738 & Gemcitabine as Combination Therapy (ATRiUM)

Cancer

United Kingdom
Nordic Bioscience A/S
Novartis

Terminated

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

Osteoarthritis

United States, Spain, Denmark, Hong Kong, Poland, Romania, Czechia, Belgium, Canada, United Kingdom

Search clinical trials for: AZD6370

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations